

## Pancreatic Cancer Committee meeting 10 Day 1 & 2

**Date:** 11/05/2017 & 12/05/2017

**Location:** RCOG, London

**Minutes:** Confirmed

<b>Committee members present:</b>	
John Primrose (Chair)	(Attended item 1 – 20)
John Neoptolemos (Clinical Lead)	(Attended item 1 – 20)
Fiona Campbell	(Attended item 1 – 20)
Richard Charnley	(Attended item 1 – 20)
Pippa Corrie	(Attended item 1 – 20)
Lesley Goodburn	(Attended item 1 – 20)
Philip Whelan	(Attended item 1 – 20)
Derek O'Reilly	(Attended item 1 – 20)
Kofi Oppong	(Attended item 1 – 20)
Anna Jewell	(Attended item 1 – 20)
Dawn Elliot	(Attended item 1 – 20)
Mark Callaway (remote attendance)	(Attended item 3 )
Laura McGeeney (remote attendance)	(Attended item 1 – 20)
Somnath Mukherjee	(Attended item 1 – 20)
Margred Capel	(Attended item 1 – 20)

<b>In attendance:</b>		
Katie Perryman Ford	NICE Guideline Commissioning Manager	(Attended item 1 – 20)
Andrew Harding	NICE Guideline Commissioning Manager	(Attended item 11 – 20)
James Hall	NICE Editor	(Attended item 1 – 20)
Angela Bennett	NGA Guideline Lead	(Attended item 1 – 20)
James Hawkins	NGA Health Economist	(Attended item 1 – 12)
Ferruccio Pelone	NGA Systematic Reviewer	(Attended item 1 – 3)
Lin Fou	NGA Systematic Reviewer	(Attended item 4 – 6 & 12)
Fionnuala O'Brien	NGA Project Manager	(Attended item 1 – 20)
<b>Observers:</b>		
Moira Mugglestone	NGA Director of Methodology	
Lisa Boardman	NGA Guideline Lead	

Alex Bates	NGA Senior Health Economist
------------	-----------------------------

**Apologies:**

Suzanne Joharchi	Committee member
John Graham	NGA Clinical Advisor

**1. Welcome and objectives for the meeting**

The Chair welcomed the Committee members and attendees to the 9<sup>th</sup> meeting on Pancreatic Cancer.

No members of the public asked to observe the meeting.

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included: reviewing evidence and agreeing recommendations on topics 3B, 3C, 3D, 5H and 4. Reviewing the edits to the recommendations, agreeing research recommendations and signing off evidence to recommendations for exiting recommendations.

**2. Declarations of interest**

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was pancreatic cancer.

The Chair asked everyone to verbally declare any interests that have arisen since the last meeting.

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Somnath Mukherjee	Senior Clinical Researcher & Consultant Clinical Oncologist, CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford & Churchill Hospital	Principal Investigator: PRECISION Panc network of clinical trials. £10 million investment from Cancer Research UK. Funding from Celgene and Astra Zeneca	Non-personal financial, specific	Declare and participate
John Neoptolemos	The Owen and Ellen Evans Chair of	On the advisory board for TARGOVAX. A Norway company	Personal non-financial, non-specific	Declare and participate

	Surgery, University of Liverpool and The Royal Liverpool & Broadgreen University Hospital NHS Trust	looking to use KRAS vaccine as part of adjuvant treatment in pancreatic cancer. 23rd March 2017.  Confidential results of a small randomised phase II trial.  A further meeting is now planned for the 22nd May 2017.		
Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust	Principal Investigator: PRECISION Panc network of clinical trials. £10 million investment from Cancer Research UK. Funding from Celgene and Astra Zeneca	Non-personal financial, specific	Declare and participate
Anna Jewell	Lay member	Provided some information on one of our funded projects to a report being put together by a group of experts called 'Transforming the cancer cycle'. The group was chaired by Katherine Murphy, Chief Executive of the Patients association and the report is available to download from their website. As a result of this I was quoted in a sponsored article in the HSJ. This work was funded by Bristol Myers Squibb. However neither I or Pancreatic Cancer UK received any funds for our contribution to this report.	Personal non-financial, non-specific	Declare and participate
Derek O'Reilly	Consultant Hepatobiliary and Pancreatic Surgeon,	Principal Investigator: PRECISION Panc network of clinical trials. £10 million	Non-personal financial, specific	Declare and participate

	Manchester Royal Infirmary, Central Manchester NHS Foundation Trust	investment from Cancer Research UK. Funding from Celgene and Astra Zeneca		
<b>3. Minutes of last meeting</b>				
<p>The Chair asked the Committee if it wanted any changes made to the minutes of the last meeting. The Committee agreed that the minutes were a true and accurate account of the meeting.</p> <p>The Chair confirmed that all matters arising had been completed or were in hand.</p>				
<b>4. Presentations</b>				
<p>The Chair introduced Ferruccio Pelone, Systematic Reviewer, who gave a presentation on the clinical evidence for topic 3C, pancreatic cysts. Ferruccio then took questions from the group. The Committee then discussed the issues presented in relation to this guideline.</p> <p>The Chair introduced Linyun Fou, Systematic Reviewer, who gave a presentation on the clinical evidence for topic 5H, biliary obstruction.</p> <p>The Chair introduced James Hawkins, Health Economist, who gave a presentation on the health economic evidence for topic 5H. Linyun and James then took questions from the Committee.</p> <p>The Chair introduced James Hawkins, Health Economist, who have a presentation on the draft economic model for 5H.</p> <p>The Chair introduced Linyun Fou, Systematic Reviewer, who gave a presentation on the clinical evidence for question 3B, people without jaundice and a pancreatic abnormality. Linyun then took questions from the group. The Committee then discussed the issues presented in relation to this guideline.</p> <p>The Chair introduced Linyun Fou, Systematic Reviewer, who gave a presentation on the clinical evidence for question 3D, inherited high risk. Linyun then took questions from the group. The Committee then discussed the issues presented in relation to this guideline.</p> <p>The Chair introduced Linyun Fou, Systematic Reviewer, who gave a presentation on the clinical evidence for question 4, staging. Linyun then took questions from the group. The Committee then discussed the issues presented in relation to this guideline.</p>				

**5. Questions and discussion**

The Committee discussed the clinical and economic evidence presented for questions 3C, 5H, 3B, 3D, topic 4. They drafted recommendations and the section of the guideline linking evidence to recommendations.

The Committee discussed the draft linking evidence to recommendations section for the recommendations drafted in GC9 and finalised them.

The Committee discussed and agreed editorial changes to the recommendations and signed off evidence to recommendations sections.

The Committee discussed and agreed the final research recommendations and prioritised the ones for the short guideline.

**6. Any other business**

No service user or carer concerns were raised.

**Date of next meeting:** 12<sup>th</sup> & 13<sup>th</sup> October 2017

**Location of next meeting:** RCOG, London